Patent ID: 11873491
Assignee: ALNYLAM PHARMACEUTICALS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 31:
32. The dsRNA agent of claim 31, wherein the sense and antisense strands consist of the nucleotide sequences selected from the group consisting of 5′-AfaGfcAfaGfaUfAfUfulifuUfaUfaAfuAf-3′ (SEQ ID NO:122) and 5′-uAfuUfaUfaAfaAfauaUfcUfuGfcUfusUfsu-3′ (SEQ ID NO:173); 5′-AfsasGfcAfaGfaUfAffifulifuUfaUfaAfuAf-3′ (SEQ ID NO:164) and 5′-usAfsuUfaUfaAfaAfauaUfcUfuGfcUfususu-3′ (SEQ ID NO:215); 5′-asasGfcAfaGfaUfAffifulifuuAfuAfaua-3′ (SEQ ID NO:2875) and 5′-usAfsUfuAfuAfAfaAfauaUfcUfuGfcuususudTdT-3′ (SEQ ID NO:2888); 5′-asasGfcAfaGfaUfAfUfuUfuuAfuAfaua-3′ (SEQ ID NO: 2876) and 5′-usAfsUfuAfuaAfaAfauaUfcUfuGfcuususudTdT-3′ (SEQ ID NO:2889); 5′-asasGfcAfaGfaUfAffifulifuuAfuaAfua-3′ (SEQ ID NO:2878) and 5′-usAfsUfuAfuAfAfaAfauaUfcUfuGfcuususudTdT-3′ (SEQ ID NO:2891); 5′-asasGfcAfaGfaUfAffifulifuuAfuaAfua-3′ (SEQ ID NO:2879) and 5′-usAfsUfuAfuaAfaAfauaUfcUfuGfcuususudTdT-3′ (SEQ ID NO:2892); 5′-asasgcaagaUfaUfuuuuauaaua-3′ (SEQ ID NO:2884) and 5′-usAfsUfuAfuAfAfaAfauaUfcUfuGfcuususudTdT-3′ (SEQ ID NO:2897); and 5′-asasgcaagaUfaUfuuuuauaaua-3′ (SEQ ID NO:2885) and 5′-usAfsUfuAfuaAfaAfauaUfcUfuGfcuususudTdT-3′ (SEQ ID NO:2898),
wherein a, g, c and u are 2′-O-methyl (2′OMe) A, G, C, and U, respectively; Af, Gg, Cf and Uf are 2′-fluoro A, G, C and U, respectively; dT is a deoxy-thymine nucleotide; and s is a phosphorothioate linkage.